MimiVax, Inc. Email Format
Biotechnology ResearchNew York, United States2-10 Employees
Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2a clinical trial in adults with newly diagnosed glioblastoma. Additional indications are being evaluated through: - Phase 1 clinical trials in multiple myeloma combination with REVLIMID® (lenalidomide) - Phase 1 in Neuro-Endocrine Tumors (NET) - Pilot Study in Pediatric High Grade Glioma, recurrent/relapsed Medulloblastoma and DIPG